title: Long-term ciclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis.
abstract: To evaluate the efficacy and safety of long-term ciclosporine A (CSA) treatment in idiopathic nephrotic syndrome, we prospectively followed immunosuppressive therapy in 22 nephrotic adults for a median of 32 months (range 7-91 months) and obtained repeat renal biopsies. CSA induced complete remission in 60.0% and 14.3% of patients with minimal change nephrotic syndrome (MCNS) (n = 7), respectively. In addition, partial remissions were achieved in 20.0% of patients with MCNS and in 42.9% of patients with FSGS. Resolution of proteinuria was strictly CSA-dependent and no sustained remission occurred following withdrawal, thereby requiring long-term treatment in 18 patients. In 10 patients CSA was administered for more than 43 months. During maintenance therapy the antiproteinuric effect of CSA was preserved and renal function as well as blood pressure remained stable in patients with MCNS, whereas renal function deteriorated in two patients with FSGS due to progression of the underlying renal disease. Renal biopsies revealed slight signs of CSA toxicity in four patients. However, in no case loss of renal function was attributable to these lesions. In conclusion, the present data suggest that long-term maintenance treatment of MCNS with CSA is efficacious and safe at least for a period of up to 43 months. In contrast, CSA has some effect on proteinuria in FSGS, but the results are less favorable.
authors.affiliation: Medizinische Klinik II, RWTH, Aachen, Germany.
authors.forename: T H
authors.initials: TH
authors.lastname: Ittel
authors.forename: W
authors.initials: W
authors.lastname: Clasen
authors.forename: M
authors.initials: M
authors.lastname: Fuhs
authors.forename: J
authors.initials: J
authors.lastname: Kindler
authors.forename: M J
authors.initials: MJ
authors.lastname: Mihatsch
authors.forename: H G
authors.initials: HG
authors.lastname: Sieberth
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009402:Nephrosis, Lipoid / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D011507:Proteinuria / Q000188:drug therapy / Q000378:metabolism*; D012074:Remission Induction
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine